期刊文献+

普米克令舒联合万托林、爱全乐雾化吸入治疗COPD的成本-效果分析 被引量:2

Cost-effectiveness analysis of Ventolin,Atrovent combined with Pulmicort respules on chronic obstructive pulmonary disease(COPD)
下载PDF
导出
摘要 目的评价普米克令舒联合万托林、爱全乐雾化吸入治疗COPD的成本-效果分析。方法将90例病人随机分为两组。治疗组:60例,给予普米克令舒联合万托林、爱全乐雾化吸入;对照组:30例,给予0.9%生理盐水,万托林、爱全乐联合雾化吸入。两组在综合疗法基础上进行。观察两组症状和临床疗效,并运用药物经济学方法成本、效果方法进行比较。结果治疗组的有效率为88.33%,对照组的有效率为80.00%,两种方案单位效果所需成本治疗组为765和对照组为1042,在对照组的基础上,增加单位效果的成本是18.92。结论药物经济分析结果为普米克令舒联合万托林、爱全乐雾化吸入优于0.9%生理盐水、万托林、爱全乐联合雾化吸入。 OBJECTIVE To evaluate the ratio of cost-effectiveness of atomized inhalation of ventolin, atrovent combined with pulmicort respules on chronic obstructive pulmonary disease. METHODS Ninety patients with bronchial asthma were randomly divided into two groups. Treatment group: 60 cases with atomized inhalation of ventolin, atrovent combined with pulmicort respules; comparison group:30 cases with atomized inhalation of 0.9 % sodium chloride, ventolin combined with atrovent. Integrative treatment measure were performed and symptom and clinical efficacy were observed in both groups, and pharmacoeconomic analysis was carried out. RESULTS Clinical total effective rate in treatment group were 88.33 %, in control group were 80.00 %. And cost-effectiveness rations were 765 and 1042 respectively. The ΔC/ΔE was 18.92. CONCLUSION Pharmacoeconomic analysis indicated that atomized inhalation of ventolin, atrovent combined with pulmicort respules was superior to atomized inhalation of 0.9 % sodium chloride, ventolin combined with atrovent.
出处 《海峡药学》 2008年第9期113-115,共3页 Strait Pharmaceutical Journal
基金 2007年江门市第三批科技计划项目 编号:03
关键词 普束克令舒 万托林 爱全乐 慢性阻塞性肺病 成本-效果分析 Pulmicort respules Ventolin Atrovent Chrordc obstructive pulmonary disease Cost-Effectiveness analysis
  • 相关文献

参考文献11

二级参考文献15

  • 1孔晓东.药物经济学:概念、方法和应用[J].国外医学(药学分册),1994,21(1):13-18. 被引量:429
  • 2小儿哮喘的治疗[J].中国实用儿科杂志,1996,11(1):1-21. 被引量:110
  • 3宋秉鹏,丁玉峰.药物经济学概述[J].药物流行病学杂志,1996,5(3):179-183. 被引量:306
  • 4黄耀诚.现代药物学[M].北京:人民军医出版社,1999.948-949.
  • 5中华人民共和国卫生部药政局.抗菌药物临床研究原则[S]..新药(西药)临床指导原则汇编[C].北京:中国医药科技出版社,1993:2..
  • 6BarnesPJ.Inhaledglucocorticoidsinasthma.In:SchleimerRP,BusseWW,O'BymePM,ed.Inhaledglucocorticoidsinasthma-mechanisnismandclinicalactions.NewYork:MarcelDekkerInc.1997:651
  • 7BoobisAR.Comparativephysicochemicalandpharmacokineticprofilesofinhaledbeclomethasonedipropionateandbudesonide.RespirMed,1998;92(supplB):2
  • 8BarnesPJ,PedersenS,BuseeWW.Efficacyandsafetyofinhaledcorticosteroidsnewdevelopments.AmJRespirCritCareMed,1998;157(3,parts):1
  • 9DerendorfH,HochhausG,MeibohmB,etal.Pharmacokineticsandpharmacodynamicsofinhaledcorticosteroids.JAllergyClinImmunol,1998;101(4,parts):440
  • 10林曦敏,徐志一,赵守军,胡德昌,张文新.上海地区α-干扰素治疗慢性乙型肝炎的药物经济学分析[J].中国临床药学杂志,1997,6(4):172-174. 被引量:6

共引文献5741

同被引文献25

  • 1陈小东.老年慢性阻塞性肺疾病的药物治疗[J].世界临床药物,2004,25(9):536-539. 被引量:2
  • 2黎东明,吴斌,樊春月.氟康唑治疗慢性阻塞性肺疾病继发呼吸道真菌感染三种给药方法的成本效果分析[J].中国基层医药,2005,12(2):191-193. 被引量:2
  • 3冉丕鑫,王辰,姚婉贞,陈萍,康健,黄绍光,陈宝元,王长征,倪殿涛,周玉民,刘升明,王小平,王大礼,吕嘉春,郑劲平,钟南山.我国部分农村地区40岁以上女性慢性阻塞性肺疾病危险因素分析[J].中华内科杂志,2006,45(12):974-979. 被引量:51
  • 4何权瀛.中国慢性阻塞性肺疾病患者现状研究主要结果.中国医学论坛报,2007,9(33):5-5.
  • 5马爱群,余保平.内科学[M].北京:人民卫生出版社,2011:256.
  • 6Beeh KM,Wiew rodt R,Salem AE,et al.Efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases[J].Pneumologie,2000,54(6):225-31.
  • 7Global initiative for chronic obstructive lung disease,pocket guide to COPD diagnosis,management,and prevention, revised 2013.
  • 8Fenton C,Keating GM.Inhaled salmeterol/flutieasone propionate: a review of its use in chronic obstructive pulmonary disease[J].Drugs, 2004,64(17): 1975-1996.
  • 9SinDD,Man SF, Mareiniuk DD,et al.The effects of flutieasone with or without salmeterol on systemic bio-markers of inflammation in chronic obstructive pulmonary disease[J].Am J ResPir Crit Care Med,2008,177(11): 1207-1214.
  • 10Chapman KR.The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease[J].Lung, 1990,168: 295-303.

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部